SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
Human recombinant endostatin preclinical studies have shown that the drug can inhibit
endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung
cancer cell apoptosis, multiple clinical studies in human recombinant endostatin combined
with chemotherapy treatment showed good antitumor efficacy and good safety.S1 is an oral
fluorouracil derivative and an improved preparation of the antitumor drug tegafur.Multiple
clinical studies have reported that S1 alone or S1 combined with chemotherapy is effective in
Non small cell lung cancer(NSCLC).Unfortunately, none of the prospective clinical studies to
date have systematically validated the safety and efficacy of antiangiogenic drugs combined
with chemotherapy in patients with advanced pulmonary SCC.The investigators expect that endu
combined with S1 will increase the efficacy of advanced lung squamous cell carcinoma.The
purpose of this study was to evaluate the objective remission rate and safety of entu
combined with oral S1 in the treatment of advanced lung squamous cell carcinoma.
Phase:
N/A
Details
Lead Sponsor:
Peking University Third Hospital
Collaborators:
Beijing 302 Hospital Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences China-Japan Friendship Hospital Dalian municipal central hospital affiliated of dalian medical university GEM flower hospital of Liaohe oil field Guangxi Ruikang Hospital Hiser Medical Center of Qingdao Liuzhou Worker's Hospital Liuzhou Workers Hospital Mianyang Central Hospital Panjin Liaohe Oilfield Gem Flower Hospital Peking University International Hospital Qingdao Hiser Medical Group Second Hospital of Shanxi Medical University Tang-Du Hospital The Affiliated Hospital of Xuzhou Medical University The fifth medical center of PLA general hospital Third Affiliated Hospital of Guizhou Medical University